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Abstract
Background: Acute calculus cholecystitis (ACC) has a high incidence in the general population. The presence of
several areas of uncertainty, along with the availability of new evidence, prompted the current update of the 2016
WSES (World Society of Emergency Surgery) Guidelines on ACC.
Materials and methods: The WSES president appointed four members as a scientific secretariat, four members as
an organization committee and four members as a scientific committee, choosing them from the expert affiliates of
WSES. Relevant key questions were constructed, and the task force produced drafts of each section based on the
best scientific evidence from PubMed and EMBASE Library; recommendations were developed in order to answer
these key questions. The quality of evidence and strength of recommendations were reviewed using the Grading
of Recommendations Assessment, Development and Evaluation (GRADE) criteria (see https://www.
gradeworkinggroup.org/). All the statements were presented, discussed and voted upon during the Consensus
Conference at the 6th World Congress of the World Society of Emergency Surgery held in Nijmegen (NL) in May
2019. A revised version of the statements was voted upon via an online questionnaire until consensus was reached.
Results: The pivotal role of surgery is confirmed, including in high-risk patients. When compared with the WSES
2016 guidelines, the role of gallbladder drainage is reduced, despite the considerable technical improvements
available. Early laparoscopic cholecystectomy (ELC) should be the standard of care whenever possible, even in
subgroups of patients who are considered fragile, such as the elderly; those with cardiac disease, renal disease and
cirrhosis; or those who are generally at high risk for surgery. Subtotal cholecystectomy is safe and represents a
valuable option in cases of difficult gallbladder removal.
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Conclusions, knowledge gaps and research recommendations: ELC has a central role in the management of
patients with ACC. The value of surgical treatment for high-risk patients should lead to a distinction between high-
risk patients and patients who are not suitable for surgery. Further evidence on the role of clinical judgement and
the use of clinical scores as adjunctive tools to guide treatment of high-risk patients and patients who are not
suitable for surgery is required. The development of local policies for safe laparoscopic cholecystectomy is
recommended.
Keywords: Acute cholecystitis, Early and delayed cholecystectomy, Surgery, Antibiotics, Gallbladder Drainage, High-
risk patients, Guidelines
Background
The estimated overall prevalence of gallstones is 10–15%
in the general population, with some differences across
countries. Between 20 and 40% of patients with gall-
stones will develop gallstone-related complications, with
an incidence of 1–3% annually; acute calculus cholecyst-
itis (ACC) is the first clinical presentation in 10–15% of
the cases [1–6]. Cholecystectomy is the most common
therapeutic approach for ACC and is considered the
standard of care for gallstone disease for the majority of
patients. However, considering the heterogeneity of clin-
ical scenarios, the variability in hospital facilities and in
the availability of expertise, the management of patients
with right upper quadrant abdominal pain may vary.
In 2016, the World Society of Emergency Surgery
(WSES) published the first edition of their guidelines for
ACC [7], which presented different diagnostic and thera-
peutic algorithms, compared with the Tokyo Guidelines
(TG), known at that time as Tokyo Guidelines 2013
(TG13) [8]. In particular, the direct link between diag-
nostic criteria for ACC, severity classification and thera-
peutic indications described in the TG13 are limited by
lack of quality evidence. The approach of the WSES
guidelines was to simplify the initial management of pa-
tients presenting with suspected ACC. The literature re-
view, the discussion of the relevant evidence and the
statements made during the consensus conference (CC)
held in Jerusalem in 2015 (Third WSES International
Congress) supported surgery as the gold standard treat-
ment for all patients with ACC, with two exceptions: pa-
tients who refuse surgery, and patients for whom
surgery would be considered as ‘very high risk’, although
no clear consensus was reached on this second issue.
Moreover, the 2016 WSES Guidelines on ACC included
discussions on unclear areas, such as diagnosis, evalu-
ation of the surgical risk and appropriate management
of associated common bile duct stones (CBDS).
In 2017, the WSES joined the Italian Society for Geri-
atric Surgery during a CC regarding the management of
ACC in the elderly, with the aim of investigating this
subgroup of fragile patients, considered at ‘very high risk’
for surgery. There was lack of agreement supporting the
surgical management of ACC in the elderly and consid-
ering old age as a contraindication for surgery by itself.
The authors found substantial lack of high-quality stud-
ies on this topic [9].
The WSES, after evaluating the 2018 edition of the
TG (TG18) on ACC [10], found that this new edition
reached conclusions that were closer to the recommen-
dations of the 2016 WSES guidelines on ACC, especially
in terms of a more liberal indication for surgery includ-
ing grade 3 ACC. However, some differences remain
when comparing the WSES guidelines and the TG (all
editions), as evident in the recommendations in the
current updated guidelines. A combined event, WSES
and TG group could be an opportunity to share experi-
ences considering different perspectives.
Since the publication of the 2016 WSES Guidelines
and the TG18, the management of the high-risk patients
with ACC was investigated in a randomized controlled
trial (RCT), known as the CHOCOLATE trial [11].
Loozen and collaborators compared cholecystectomy to
percutaneous catheter drainage in high-risk surgical pa-
tients. This research group has joined with other experts
in contributing to this edition of the WSES guidelines
on ACC.
Materials and methods
In 2018, the Scientific Board of the 6thWorld Congress
of the WSES endorsed its president to organize a CC on
ACC in order to update the previous WSES Guidelines.
The WSES president appointed four members as a sci-
entific secretariat, four members as an organization
committee and four members as a scientific committee,
choosing them from the expert affiliates of the WSES.
Relevant key questions regarding the diagnosis and treat-
ment of ACC were developed and divided into seven
sections, in order to analyse the topic and update the
guidelines with the currently available evidence. Under
the supervision of the scientific secretariat, a biblio-
graphic search related to these questions was performed,
using electronic search of PubMed and EMBASE data-
bases in May 2019, with no date or language restrictions.
An additional manual search of the literature was
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performed by members of the working groups involved
in the analysis of the papers and the development of the
guidelines. The topics and sections, the key questions
and the related key words used to develop the update on
ACC are available in Table 1.
Before the CC, the statements and recommendations
were reviewed by the representatives responsible for
each of the sections, creating a draft version of the
guidelines. The quality of evidence and strength of rec-
ommendations were reviewed using the Grading of Rec-
ommendations Assessment, Development and
Evaluation (GRADE) criteria (see https://www.gradewor-
kinggroup.org/). Specifically, the quality of evidence was
graded as ‘High’, ‘Moderate’, ‘Low’ or ‘Very low’ and the
strength of a recommendation was indicated as either
‘Strong’ or ‘Weak’. Consensus had previously been de-
fined as 70% or more of the votes being in agreement.
During the 6th World Congress of the WSES held in
Nijmegen, the Netherlands in May 2019, each question
was discussed and voted upon by the audience (votes
were either ‘agree’ or ‘disagree’). The percentage of
agreement was recorded immediately; in case of dis-
agreement, the statement was modified following discus-
sion. After the CC, the president and representatives
reviewed the guidelines in response to the comments
and the revised version of the statements was voted
upon via an online questionnaire until consensus was
reached. Throughout the period of the elaboration of the
current guidelines, repeated literature searches were car-
ried out in order to maximize the inclusion of relevant
evidence (last literature search: May 2020).
These Guidelines should be considered an adjunctive
tool for decision making, but they are not a substitute
for the surgeon’s judgement in specific clinical
situations.
In Appendix 1, the reader can find the summary of
statements with short explanation of the supporting sci-
entific evidence while details are in the body of the
paper. Figure 1 represents the 2020 WSES flowchart for
the management of ACC patients.
The WSES committee for guidelines development is
responsible for the continuous evaluation of evidence
available about acute cholecystitis. The present guide-
lines will be updated in case of significant changes based
on new evidence.
Section 1. Diagnosis of ACC
1.1 As no feature has sufficient diagnostic power to
establish or exclude the diagnosis of ACC, it is rec-
ommended not to rely on a single clinical or labora-
tory finding. #QoE: high; SoR: strong#
1.2 For the diagnosis of ACC, we suggest using a
combination of detailed history, complete clinical
examination, laboratory tests and imaging
investigations. However, the best combination is not
known. #QoE: very low; SoR: weak#
Comment: useful features for the diagnosis of ACC
are:
 History and clinical examination: fever, right upper
quadrant pain or tenderness, vomiting or food
intolerance; Murphy’s sign
 Laboratory tests: elevated C-reactive protein, ele-
vated white blood cell count
 Imaging: signs suggestive of gallbladder
inflammation
The recommendations of the 2016 WSES guidelines
were mainly based on two studies: a systematic review
and meta-analysis by Trowbridge et al. [12] and a pro-
spective diagnostic study by Eskelinen et al. [13]. This
evidence, although flawed by the limitations described
below, remains relevant and the associated statement re-
mains valid.
The paper by Trowbridge et al. [12] included 17 stud-
ies, which reported a quantitative assessment of history,
physical examination and/or laboratory tests for the
diagnosis of acute cholecystitis. The results showed that,
with the exception of Murphy’s sign (positive likelihood
ratio—LR 2.8; 95% CI 0.8–8.6) and right upper quadrant
tenderness (negative LR0.4; 95% CI 0.2–1.1)—although
the 95% confidence intervals included 1.0 in both cases,
none of the clinical signs or laboratory tests showed LRs
higher than 1.6 or negative LRs lower than 0.4. Limita-
tions were identified in a possible selection bias, as pa-
tients with abdominal pain and patients with a suspected
diagnosis of acute cholecystitis were included in the
study, and in a heterogeneous definition of the diagnosis
of acute cholecystitis.
The article by Eskelinen et al. [13] evaluated more
than 1300 patients and revealed a good diagnostic yield
with a combination of findings from history, physical
examination and laboratory tests, reporting a positive LR
of 25.7 and a negative LR of 0.24.
The TG criteria for the diagnosis of cholecystitis in-
clude clinical signs, laboratory tests and imaging features
[14]. After the publication of the paper by Yokoe et al.
in 2012 [15] reporting 91.2% sensitivity and 96.9% speci-
ficity, three studies reporting the validation of the TG
diagnostic criteria were found. Although published in
2017, one study focused on the TG07 rather than the
more recent TG13 [16]. A cross-sectional study [17]
evaluated the validity of fever, inflammatory markers
and US findings as a validation of the TG13 criteria. At
multivariate analysis, only neutrophil count was statisti-
cally associated with the diagnosis of acute cholecystitis
(p <0.0001), with a 70% sensitivity and 65.8% specificity.
Overall, accuracy of the TG13 criteria was low at 60.3%.
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Table 1 Sections/topics, key questions and key words
Section/topic Key questions Key words
1. Diagnosis of Acute Calculus Cholecystitis Which is the most reliable approach for the
diagnosis of ACC?
Which initial imaging technique should be used
in case of a suspected diagnosis of ACC?
Which is the role of other imaging techniques
(e.g. Hepatobiliary iminodiacetic acid—HIDA scan,
abdominal computed tomography—CT scan and
magnetic resonance) in the diagnosis of ACC?
Acute calculus cholecystitis Diagnosis, Ultrasound,
Gallstones disease diagnosis
2. Associated common bile duct stones
(CBDS)
Are elevated LFTs or bilirubin sufficient for the
diagnosis of CBDS in patients with ACC?
Which imaging features are predictive of CBDS in
patients with ACC?
Which tests should be performed to assess the
risk of CBDS in patients with ACC?
Which is the best tool to stratify the risk for CBDS
in patients with ACC?
Which actions are warranted in patients with ACC
and at moderate for CBDS?
Which actions are warranted in patients with ACC
and at high risk for CBDS?
Which is the appropriate treatment of CBDS in
patients with ACC?
Common bile duct stone; choledocholithiasis;
endoscopic ultrasound, MRCP, ERCP
3. Surgical treatment of acute calculus
cholecystitis
Which is the preferred first line of treatment for
patients with ACC?
When should laparoscopic cholecystectomy be
avoided in patients with ACC?
Is laparoscopic cholecystectomy safe and feasible
for patients with ACC who have liver cirrhosis,
who are older than 80 years and who are
pregnant?
Which surgical strategies should be adopted in
case of difficult anatomic identification during
cholecystectomy for ACC?
When should conversion from laparoscopic to
open cholecystectomy be considered in patients
with ACC?




4. Timing of cholecystectomy in people with
acute calculus cholecystitis
Which is the optimal timing for laparoscopic
cholecystectomy in patients with ACC?
Acute calculus cholecystitis, acute cholecystitis
5.Risk prediction in patients with acute
calculus cholecystitis
How can the prognosis and surgical risk be
assessed for patients with ACC?
Acute calculus cholecystitis, Gallstone disease,
Surgical risk score, High risk patient, old patient,
PPossum score, Apache score
6. Alternative treatment for patients who are
not suitable for surgery: non-operative man-
agement and gallbladder drainage
techniques
When should Non-Operative Management (NOM)
be considered for patients with ACC?
Which is the first-choice treatment for ACC in
high risk patients?
Which is the role of gallbladder drainage in
patients with ACC who are not suitable for
surgery?
Should delayed cholecystectomy be offered to
patients with ACC after the reduction of
perioperative risk?
Can endoscopic gallbladder drainage be
considered an alternative to PTGBD in patients
with ACC who are not suitable for surgery?
Which is the role of endoscopic transmural
ultrasound-guided gallbladder drainage (EUS-
GBD) in patients with ACC who are not suitable
for surgery?
Gallstones Dissolution, No-surgery gallstones,
Extra-corporeal shock wave lithotripsy, Acute cal-
culus cholecystitis, Gallstone disease, Manage-
ment Gallstones, Endoscopy, Gallstone removal,
Observation cholecystitis, Non operative manage-
ment cholecystitis, Gallbladder drainage Percutan-
eous gallbladder drainage, Cholecystostomy, High
Risk Patient, Stent
7. Antibiotic treatment on acute calculus
cholecystitis
Which is the optimal antibiotic treatment for
patients with uncomplicated ACC?
Which is the optimal antibiotic treatment for
patients with complicated ACC?
Which is the role of microbiological cultures and
sensitivities in patients with ACC?
Antibiotics, Acute calculus cholecystitis, Gallstone
disease, Management Gallstones
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The TG13 correctly predicted 83.1% of all confirmed
ACC, but over-diagnosed ACC in 62.5% of normal gall-
bladders. More than half of eligible patients did not
undergo US and were excluded from the study; this rep-
resents a major source of potential selection bias. A
cross-sectional study on the possible limitations of the
TG 13 has reported a 53.4% sensitivity in diagnosing
acute cholecystitis [18]. However, some uncertainty re-
garding the sample population and the lack of detail in
sensitivity calculation indicates that the data should be
interpreted with caution. The revision of the TG criteria
performed in 2018 did not include a clinical evaluation
of the diagnostic criteria [14]. Considering the hetero-
geneity of these findings, the reliability of the TG13 cri-
teria for the diagnosis of ACC appears to be limited.
Which initial imaging technique should be used in
case of a suspected diagnosis of ACC?
1.3 We recommend the use of abdominal ultra-
sound (US) as the preferred initial imaging
technique, in view of its cost-effectiveness, wide
availability, reduced invasiveness and good accuracy
for gallstones disease. #QoE: high; SoR: strong#
Comment: abdominal US is a reliable investigation
method; however, it may be of limited utility to rule in
or rule out the diagnosis of ACC according to the
adopted US criteria.
Neither meta-analysis nor studies with adequate qual-
ity of evidence have been published on this topic since
the publication of the 2016 WSES guidelines.
In 2012, Kiewet et al. published a systematic review
and meta-analysis [19] of diagnostic performance of
different imaging techniques in ACC; abdominal
ultrasound was not as accurate as it is for the diagnosis
of gallstones. The meta-analysis was based on the results
Fig. 1 2020 WSES Flowchart for the management of patients with acute calcolus cholecystitis
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of 26 studies including a total of 2847 patients. The sen-
sitivity in individual studies ranged from 50 to 100% and
specificity from 33 to 100%. Summary sensitivity and
specificity were 81% (95% CI 75 to 87%) and 83% (95%
CI 74 to 89%), respectively. However, strong heterogen-
eity in the diagnostic performance of abdominal US was
reported: the inconsistency index was 80% for sensitivity
and 89% for specificity. Notwithstanding these limita-
tions, the widespread availability, lack of invasiveness,
lack of exposure to ionizing radiation and the reduced
costs make abdominal US the preferred initial imaging
technique in suspected ACC.
Published data from eight cross-sectional studies [20–
27] confirmed the heterogeneity of diagnostic values,
diagnostic index and standard reference for the final
diagnosis of ACC. Traditional US presented wide ranges
of sensitivity (from 26 to 100% [20–26]), specificity
(from 62 to 88.1% [22–27]), positive predictive value
(PPV) and negative predictive value (NPV 35% to 93.7%
and 52% to 97.1%, respectively), as well as positive LR
(1.29 to 4.7) and negative LR (0.16 to 0.93) [23, 24]. Glo-
bal accuracy has been reported in two studies and varied
from 70.1 to 79% [26, 27].
In one study, the absence of gallstones was used to
rule out the diagnosis of acute cholecystitis in pa-
tients presenting to the emergency department for
suspected cholecystitis [23]. Overall, the sensitivity of
the simplified definition of a positive ultrasonography
test was100%, as compared to the standard definition,
i.e. the presence of gallstones and at least one of the
ultrasonography signs of acute cholecystitis, which
showed a sensitivity of 87% (95% CI 66–97%) and
specificity of 82 (95% CI 74–88%); prevalence was less
than 15%, NPV was 97% (95% CI 93–-99%) and PPV
was low at 44% (95% CI 29–59%).
Considering the limits of abdominal US, one study has
evaluated new ultrasonography criteria for the diagnosis
of acute cholecystitis. Kim et al. [26] evaluated the added
value of point shear-wave elastography (pSWE) in the
diagnostic performance of conventional US for the diag-
nosis of ACC. Based on the assumption that transient
increase in hepatic blood flow observed in case of acute
cholecystitis increases liver stiffness, the authors pro-
posed to use a measure of liver stiffness by pSWE and to
evaluate its diagnostic yield for ACC in a two-observer
analysis. Compared to conventional US, pSWE signifi-
cantly increased diagnostic accuracy (area under the
curve—AUC from 79 to 96.3% and from 77 to 96.2%, p
< 0.001) and specificity (from 62 to 95%, p < 0.001). The
difference in sensitivity was not significant, being 88
versus 92% (p = 0.45) in the US only group and 86–92%
(p = 0.26) in the US plus pSWE group. Although the re-
sults appear promising, the technique requires expertise;
moreover, 18.5% of patients were excluded due to a
potential limitation of the technique, therefore reducing
the external validity of the study.
Another study by Ra et al. [27] has reported the use of
superb microvascular imaging (SMI) in the diagnosis of
acute cholecystitis. The SMI technique is similar to Color-
Doppler US and is used to detect the micro vasculature
and slow flow of the liver, using a special filtering tech-
nique. The authors hypothesised that hyperaemic changes
within the gallbladder bed of the liver, detected by SMI,
and may be used for the diagnosis of acute cholecystitis.
This inter-observer study on 54 patients showed a signifi-
cant increase of the AUC from 72.9 to 85% (p = 0.02) with
the use of SMI. The need for specific expertise, the small
number of patients and the poor reference standard limit
the significance of this study.
What is the role of other imaging techniques (e.g.
Hepatobiliary iminodiacetic acid - HIDA scan, Ab-
dominal Computed Tomography - CT scan and
Magnetic Resonance Imaging - MRI) in the diagno-
sis of ACC?
1.4 We suggest the use of further imaging for the
diagnosis of ACC in selected patients, depending on
local expertise and availability. Hepatobiliary imino-
diacetic acid (HIDA) scan has the highest sensitivity
and specificity for the diagnosis of ACC as compared
to other imaging modalities. Diagnostic accuracy of
computed tomography (CT) is poor. Magnetic reson-
ance imaging (MRI) is as accurate as abdominal US.
#QoE: moderate; SoR: strong#
Comment: in clinical practice, HIDA scan utilisation is
limited due to the required resources and time.
No study with a high level of evidence was published
on this topic since the publication of the 2016 WSES
guidelines.
A cross-sectional study [28] evaluated the incremental
benefits of cystic duct enhancement detected by CT for
the diagnosis of cholecystitis in patients without visibly
impacted gallstones. When considering cystic duct en-
hancement, the accuracy and sensitivity of the diagnosis
increased significantly, while no significant difference
was reported for specificity. Interestingly, diagnostic ac-
curacy increased for the less experienced radiologist,
from 75.4 to 87.3% (p = 0.015). However, this case con-
trol study has some methodological flaws limiting its
quality.
A study considering only patients with a definitive
diagnosis of acute cholecystitis compared the diagnostic
sensitivities of US, CT and HIDA scan [20]. The results
confirmed the higher sensitivity of HIDA over US and
CT with respective values of 84.2%, 67.3% and 59.8% (p
= 0.017). No difference was found when comparing CT
and US (p = 0.09).
A study comparing sensitivity of CT and US [21]
showed different results, reporting higher sensitivity of
Pisano et al. World Journal of Emergency Surgery           (2020) 15:61 Page 6 of 26
CT, compared with US(92% vs. 79%, p = 0.015). In this
study, a retrospective cohort of patients was added based
on prospectively collected data from patients with a
diagnosis of ACC confirmed by pathology or intra-
operative findings. Indication for CT and timing between
index and reference standards were not reported.
One study on a time-saving HIDA scan technique
reported a high inter-rate agreement (Cohen’s kappa
coefficient = 0.92) between the novel time-saving
technique and the conventional examination [29].
Two other studies reported diagnostic values of HIDA
scan as 86.7–89.3% for sensitivity and 66.8–79% for
specificity [21, 22].
Section 2. Associated common bile duct stones:
which tools to use for suspicion and diagnosis at
presentation?
Choledocholithiasis, i.e. the presence of common bile
duct stones (CBDS), is reported to occur in 10% to 20%
of gallstone cases, with lower incidence, ranging from 5
to 15 %, in case of ACC [30–33]. Investigations for
CBDS require time and may delay surgical treatment.
Due to the relatively low incidence of CBDS during
ACC, the main issue is to select patients with a high
likelihood of CBDS, who would benefit from further
diagnostic tests and removal of CBDS. An uncommon
condition that mimics CBDS is Mirizzi syndrome, which
occurs in less than 1% of patients with gallstones. Pre-
operative investigations may help in the diagnosis, al-
though the vast majority of cases are identified at
surgery [34, 35].
The only new study on this topic was a cross-sectional
study on the role of liver function tests (LFTs) [36]. The
authors evaluated the role of LFTs and the role of early
follow-up in the diagnosis of CBDS in ACC. The most
reliable LFT was gamma-glutamyl transpeptidase (GGT),
with a sensitivity of 80.6% and a specificity of 75.3%,
using a cut-off level of 224 IU/L. PPV was 50%, while
NPV was 91.4%. The results also showed a significant
decrease of LFTs within the non-CBD groups at 4-day
follow-up, which was not evident in the ACC + CBDS
group—with the exception of alanine aminotransferase
(ALT). Moreover, in the CBDS group, all LFTs values
improved significantly after the removal of the CBDS at
a mean follow-up time of 4.3 days.
One flaw of the study is that index diagnosis depends
to some extent on the reference standard. Given the
retrospective design of the study, it should be considered
that the diagnosis of CBDS is assessed with endoscopic
retrograde cholangio-pancreatography (ERCP), which is
mainly prompted by the presence of elevated LFTs; this
may represent a source of bias. No systematic intra-
operative cholangiography (IOC) was performed.
Are elevated LFTs or bilirubin sufficient for the
diagnosis of CBDS in patients with ACC?
2.1 We recommend against the use of elevated
LFTs or bilirubin as the only method to identify
CBDS in patients with ACC, in which case we recom-
mend performing further diagnostic tests. #QoE:
moderate; SoR: strong#
Historically, LTFs have played a major role in deter-
mining the presence of CBDS. However, the majority of
published studies did not consider patients with ACC
and included asymptomatic gallstones. Normal LFTs
have a NPV of 97%, whereas the PPV of any abnormal
LFTs is only 15% [37]. The elevation of LFTs is a poor
tool for the prediction of CBDS, even in patients without
ACC; the literature ranging from 25 to 50% [30, 38, 39].
In patients with ACC, LFTs may be altered due to the
acute inflammatory process of the gallbladder and the
biliary tree, rather than direct biliary obstruction; a pro-
portion ranging between 15 and 50% of patients with
ACC show elevation in LFTs without CBDS. Song et al.
demonstrated that 424 out of 1178 patients with ACC
had increased LFTs, namely ALT and aspartate trans-
aminase (AST) greater than twice reference levels. Of
these, only 246 (58%) had CBDS [40]. Chang et al.
showed that 51% and 41% of patients with ACC without
CBDS had elevated ALT and AST, respectively. How-
ever, increased bilirubin levels with leucocytosis may
predict gangrenous cholecystitis [41]. Padda et al. found
that approximately 30% of patients with ACC without
CBDS had abnormal alkaline phosphatase (ALP) and/or
bilirubin, and 50% had abnormal ALT. Among patients
with ACC and CBDS, 77% had raised ALP, 60% had ab-
normal bilirubin and 90% had elevated ALT; multivariate
analysis showed that increased common bile duct size
and elevated ALT and ALP were predictors of CBDS
[42]. The diagnostic accuracy increases for cholestasis
tests, such as serum bilirubin, with the duration and the
severity of obstruction. Specificity of serum bilirubin
levels for CBDS was 60% with a cut-off level of 1.7 mg/
day and 75% with a cut-off level of 4 mg/dl [38]; how-
ever, mean level of bilirubin in patients with CBDS is
generally lower (1.5 to 1.9 mg/dl) [30, 39].
A recent meta-analysis reported the diagnostic ac-
curacy of serum bilirubin and serum ALP at two cut-
off values for each test. Serum bilirubin at a cut-off
of 22.23 μmol/L had a sensitivity of 0.84 (95% CI
0.65 to 0.94) and a specificity of 0.91 (95% CI 0.86 to
0.94). Bilirubin at a cut-off of greater than twice the
normal limit, had a sensitivity of 0.42 (95% CI 0.22 to
0.63) and a specificity of 0.97 (95% CI 0.95 to 0.99).
For ALP at a cut-off of greater than 125 IU/L, sensi-
tivity was 0.92 (95% CI 0.74 to 0.99) and specificity
was 0.79 (95% CI 0.74 to 0.84). For ALP at a cut-off
of greater than twice the normal limit, sensitivity was
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0.38 (95% CI 0.19 to 0.59) and specificity was 0.97
(95% CI 0.95 to 0.99) [43].
Which imaging features are predictive of CBDS in
patients with ACC?
2.2 We suggest considering the visualization of a
stone in the common bile duct at transabdominal US
as a predictor of CBDS in patients with ACC. #QoE:
very low; SoR: weak#
2.3 An increased diameter of common bile duct, an
indirect sign of stone presence, is not sufficient to
identify ACC patients with CBDS and we therefore
recommend performing further diagnostic tests.
#QoE: high; SoR: strong#
Abdominal US is the preferred imaging technique for
the diagnosis of ACC; the common bile duct can be vi-
sualized and investigated at the same time. A meta-
analysis by Gurusamy et al. investigated the diagnostic
potential of US [43]: sensitivity ranged from 0.32 to 1.00
with a summary sensitivity of 0.73 (95% CI 0.44 to 0.90),
while specificity ranged from 0.77 to 0.97 with a sum-
mary specificity of 0.91 (95% CI 0.84 to 0.95).
In a retrospective analysis, Boys et al. [44] found that
the mean common bile duct diameter seen at abdominal
US in ACC patients without and with CBDS was 5.8 and
7.1 mm, respectively (p = 0.004). A CBD diameter larger
than 10 mm was associated with a 39 % incidence of
CBDS, while diameter smaller than 9.9 mm was associ-
ated with CBDS in 14%. The authors concluded that
common bile duct diameter is not sufficient on its own
to identify patients having significant risk for CBDS.
Which tests should be performed to assess the risk of
CBDS in patients with ACC?
2.4 In order to assess the risk for CBDS, we suggest
performing liver function tests (LFTs), including
ALT, AST, bilirubin, ALP, GGT and abdominal US in
all patients with ACC. #QoE: low; SoR: weak#
Several scores for the prediction of CBDS have been
proposed and validated; however, none of the proposed
scores is specific for ACC. The implementation of these
predictive scores in clinical practice remains poor [38–
40]; all scores consider different combinations of the
same clinical variables. Barkun et al. [38] combined age
> 55 years, elevated serum bilirubin, dilated common
bile duct and evidence of CBDS; Menezes et al. [45]
combined age > 55 years, male sex, ascending cholan-
gitis, dilated common bile duct, CBDS and abnormal
LFTs; Soltan et al. [46] included history of symptomatic
disease, abnormal liver function tests, dilated common
bile duct and presence of CBDS; Sun et al. [47] included
male sex, abnormal liver function test and dilated com-
mon bile duct; Sarli et al. [48] combined positive AUS
and abnormal liver function tests.
The American Society of Gastrointestinal Endoscopy
and the Society of American of Gastrointestinal
Endoscopic Surgeons combined the published validated
clinical scores and proposed a risk stratification of CBDS
in three different classes, defined as follows: low risk (<
10%), moderate risk (10 to 50%) and high risk (> 50%) of
CBDS [49] (see Table 2). This proposed classification
has clear clinical implications: patients with a low risk of
CBDS should be operated on without further investiga-
tion; patients with moderate risk should be evaluated
with a second-level examination, either preoperatively
with endoscopic US (EUS) or magnetic resonance cho-
langiopancreatography (MRCP) or intraoperatively with
laparoscopic US (LUS) or IOC, in order to select pa-
tients who need stone removal; finally, according to local
expertise, laparoscopic transcystic CBD exploration is a
valuable option. Patients with high risk of CBDS should
undergo preoperative diagnostic and therapeutic ERCP.
See Fig. 1 for the flowchart of management of ACC.
What is the best tool to stratify the risk for CBDS in
patients with ACC?
2.5 We suggest stratifying the risk of CBDS accord-
ing to the proposed classification modified from the
American Society of Gastrointestinal Endoscopy and
the Society of American Gastrointestinal Endoscopic
Surgeon Guidelines. #QoE: very low; SoR: weak#
ASGE guidelines remains a valuable tool for the
diagnosis and the management of CBDS in patients
with ACC [49]. According to their classification, high-
risk patients have a probability of having CBDS ex-
ceeding 50%, which in turn means that up to 49% of
patients undergoing ERCP will not have evidence of
CBDS and, given the potential complications of ERCP,
this may not be considered acceptable. For this rea-
son, we would recommend more cautious approach:
only patients with evidence of CBDS at abdominal US
should be considered at high risk of CBDS and
should undergo diagnostic and therapeutic ERCP dir-
ectly; patients with total serum bilirubin > 4 mg/dl or
enlarged common bile duct diameter at US with con-
comitant bilirubin level 1.8 to 4 mg/dl should be con-
sidered as moderate risk and should undergo second
level investigation such as endoscopic ultrasound
(EUS) or magnetic resonance cholangiopancreatogra-
phy (MRCP), laparoscopic ultrasound (LUS) or IOC,
in order to avoid the complications related to ERCP.
See Table 2 for the modified risk stratification.
Which actions are warranted in patients with ACC
and at moderate risk for CBDS?
2.6 We recommend that patients with moderate
risk for CBDS undergo one of the following: pre-
operative magnetic resonance cholangiopancreato-
graphy (MRCP), preoperative endoscopic ultrasound
(EUS), intraoperative cholangiography (IOC), or lap-
aroscopic ultrasound (LUS), depending on local ex-
pertise and availability. #QoE: high; SoR: strong#
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Two preoperative imaging techniques are available for
the detection of CBDS, namely MRCP and EUS. These
diagnostic tests, according to the ASGE guidelines [49]
should be reserved for patients with moderate risk for
CBDS and have been shown to delay definitive ACC
treatment [44]. On the other hand, these tests could
exclude the presence of CBDS with high diagnostic ac-
curacy, thereby avoiding further inappropriate invasive
procedures, such as ERCP or IOC and therefore their
complications. In fact, the implementation of these tech-
niques resulted in a reduction of ERCP by 30 to 75% in
non-selected patients [50, 51]. A Cochrane meta-analysis
compared these two different techniques [52]: both had
good diagnostic accuracy, showing summary sensitivities
of 95% for EUS and 93% for MRCP and a summary spe-
cificity of 97% and 96%, respectively. As noted by some
authors, considerations other than diagnostic efficacy,
such as local availability, costs, expertise and delay of
surgery, might play an important role in the decision
making during the diagnostic work-up [53].
Which actions are warranted in patients with ACC
and at high risk for CBDS?
2.7 We recommend that patients with high-risk for
CBDS undergo preoperative ERCP, IOC or LUS, de-
pending on the local expertise and the availability of
the technique. #QoE: high; SoR: strong#
ERCP has both a diagnostic and a therapeutic role in
the management of CBDS, but it is an invasive procedure
with potential severe complications. The literature under-
scores the risks of diagnostic ERCP. Morbidity associated
with diagnostic ERCP includes pancreatitis, cholangitis,
bleeding, duodenal perforation and allergic reaction to
contrast medium. Complications occur in 1 to 2% and in-
crease to 10% when associated with sphincterotomy [54–
57]. On the other hand, IOC significantly increases the
length of surgery [58] and requires dedicated staff in the
operating room, while this may not be available, espe-
cially in the acute setting with unplanned surgery.
Positive findings on IOC often lead to intraoperative
management of CBDS with additional operative time.
A recently published meta-analysis compared ERCP
and IOC [58]. The summary sensitivity for ERCP was
0.83 (95% CI 0.72 to 0.90) and specificity was 0.99 (95%
CI 0.94 to 1.00). For IOC, the summary sensitivity was
0.99 (95% CI 0.83 to 1.00) and specificity was 0.99 (95%
CI 0.95 to 1.00). Sensitivities showed a weak statistical
difference (p = 0.05); however, due to the low quality
and the methodology of the included studies, the two
diagnostic techniques should be considered equivalent.
LUS is a useful method for intraoperative detection of
CBDS [59]. A meta-analysis has shown that IOC and
LUS have the same pooled sensitivity and similar pooled
specificity for the detection of CBDS [60]. As in the case
of IOC, intraoperative evidence of CBDS with LUS leads
to intraoperative management of common bile duct with
increased operative time.
Which is the appropriate treatment of CBDS in pa-
tients with ACC?
2.8 We recommend removing CBDS, either pre-
operatively, intraoperatively, or postoperatively,
according to the local expertise and the availability of
several techniques. #QoE; high; SoR: strong#
CBDS could be removed with several techniques and a
variation of timing (see Fig. 1): preoperative ERCP with
sphincterotomy, intraoperative ERCP with sphincterot-
omy, laparoscopic or open common bile duct explor-
ation, post-operative ERCP with sphincterotomy. A
systematic review assessed the differences between these
techniques [61]. No differences in terms of morbidity,
mortality and success rate were reported. Therefore,
these techniques can be considered suitable options, de-
pending on local expertise and availability. Another
meta-analysis compared preoperative and intraoperative
(rendez-vous technique) ERCP with sphincterotomy
[62]. These two techniques were equal in terms of safety
and efficacy; the intraoperative technique reduced the
Table 2 Risk factors and classification of risk for CBDS (modified from Maple et al. 2010)
Very strong Evidence of CBDS stone at the abdominal ultrasound
Ascending cholangitis
Strong Common bile duct diameter > 6 mm (with gallbladder in situ)
Total serum bilirubin level > 1.8 mg/dl
Moderate Abnormal liver biochemical test other than bilirubin
Age older than 55 years
Clinical gallstone pancreatitis
Risk class for choledocolithiasis
High Presence of any very strong
Low No predictors present
Intermediate All other patients
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risk for post-ERCP pancreatitis, but required dedicated
staff and prolonged the length of surgery.
Section 3. Surgical treatment of ACC
The literature updated from the 2016 WSES Guidelines
on ACC showed no remarkable publications to change
the meaning of previous statements edited by the WSES
in 2016 [7]; however, they have been reviewed to ensure
the best available evidence.
Which is the preferred first line of treatment for
patients with ACC?
When should laparoscopic cholecystectomy be
avoided in patients with ACC?
3.1 We recommend laparoscopic cholecystectomy
as the first-line treatment for patients with ACC.
#QoE: high; SoR: strong#
Comment: A low complication rate and shortened
hospital stay are the major advantages.
3.2 We recommend avoiding laparoscopic chole-
cystectomy in case of septic shock or absolute anaes-
thesiology contraindications. #QoE: high; SoR:
strong#
Laparoscopic cholecystectomy is generally considered
the standard technique for the removal of gallstones.
Local inflammation, especially in gangrenous and em-
physematous ACC, has been considered to increase the
risk of bile duct injuries, blood loss, operative time, gen-
eral morbidity and mortality rates in comparison with
open surgery [63]. As technical difficulties usually de-
crease with experience and improvements in surgical
technique and instrumentation, the hesitation to safely
perform laparoscopic cholecystectomy in ACC has de-
creased over the years.
Despite several studies, ranging from case series to
randomized prospective clinical trials, confirming the
feasibility and safety of laparoscopic cholecystectomy in
the treatment of patients with ACC [64–73], a recent
survey on intra-abdominal infection, the CIAOW study
[74], showed unexpected results. It was a worldwide sur-
vey of 68 medical institutions during a 6-month study
period demonstrating that 48.7% of patients with ACC
still underwent open surgery.
Nevertheless, evidence has clearly shown the safety of
laparoscopic cholecystectomy in ACC. A recent system-
atic review, comparing open versus laparoscopic
cholecystectomy, summarized the available evidence,
underlining the limitations and providing a qualitative
and quantitative analysis of the included studies. Of 651
studies, 10 were included after qualitative analysis
(published between 1993 and 2012): four RCTs, two pro-
spective non-randomized studies, and four retrospective
trials, including 1374 patients (677 by laparoscopy vs.
697 by open surgery).
Laparoscopic cholecystectomy in ACC was associated
with a lower complication rate and with a shorter
hospital stay. There were no differences for the same-
admission cholecystectomy in terms of morbidity, opera-
tive time and intraoperative blood loss and bile leakage;
however, the laparoscopic approach showed a decrease
in mortality rate, postoperative hospital stay, wound in-
fection and pneumonia. Moreover, the operative time
progressively became shorter in laparoscopy when data
were analysed its instances between 1998 and 2007 [75].
A reaffirmation of the safety of laparoscopic cholecyst-
ectomy for ACC was shown in another systematic re-
view comparing early laparoscopic cholecystectomy
(ELC) and delayed laparoscopic cholecystectomy (DLC),
including seven discordant meta-analyses and systematic
reviews published from 2004 to 2015. The conclusions
were that no differences in mortality, bile duct injury,
bile leakage, overall complications and conversion to
open surgery were seen. However, ELC had a significant
reduction in wound infection, hospitalisation, duration
of surgery and quality of life [76].
TG18 widened the indications for laparoscopic chole-
cystectomy when compared with TG13, as they sup-
ported same-admission laparoscopic cholecystectomy for
patients with all three severity grades of ACC [77, 78].
This is in line with the recommendations of the 2016
WSES Guidelines [7].
In summary, the review of the relevant recent litera-
ture confirmed strong support for the recommendation
that laparoscopic cholecystectomy should be attempted
in cases of ACC. Critical patient conditions, such as sep-
tic shock or anaesthesiology contraindication, are rea-
sons to avoid laparoscopic cholecystectomy.
Is laparoscopic cholecystectomy safe and feasible for
patients with ACC who have liver cirrhosis, are older
than 80 years or are pregnant?
3.3 We suggest performing laparoscopic cholecyst-
ectomy for ACC patients with Child’s A and B
cirrhosis, patients with advanced age (including more
than 80 years old) and patients who are pregnant.
#QoE: low; SoR: weak#
Patients with liver cirrhosis
In cases of liver cirrhosis, surgical dissection could be
difficult and there is a higher risk of bleeding and other
serious complications. Unfortunately, the available evi-
dence on both open and laparoscopic cholecystectomy
for ACC in patients with liver cirrhosis is limited. There-
fore, we mainly accept evidence that comes from elective
procedures performed for biliary colic or chronic chole-
cystitis. According to a meta-analysis published by de
Goede et al., elective laparoscopic cholecystectomy in
patients with child A or B cirrhosis was associated with
significantly fewer postoperative complications, a shorter
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duration of hospitalisation and a shorter time to resume
a normal diet, when compared to the open technique
[79]. Lucidi et al. recommended laparoscopic cholecyst-
ectomy as the first-choice approach in cirrhotic patients.
However, recommendation for laparoscopic cholecystec-
tomy in patients with child C cirrhosis is unclear [80].
Nevertheless, other studies showed that laparoscopic
cholecystectomy in these cirrhotic patients was associ-
ated with a significantly prolonged duration of surgery
and an increase in operative blood loss, conversion rate,
length of hospital stay and overall morbidity and mortal-
ity when compared with non-cirrhotic patients [81]. In
cirrhotic patients, the morbidity associated with laparo-
scopic cholecystectomy is directly related to the Child-
Pugh score [82, 83].
In patients with advanced cirrhosis and severe portal
hypertension, specific technical difficulties may be en-
countered due to the presence of a portal cavernoma,
the difficulty in dissecting the Calot’s triangle and the
gallbladder hilum, the presence of adhesions and neovas-
cularization or difficulty in controlling bleeding from the
liver bed. Subtotal cholecystectomy is a valid option to
avoid some of these difficulties [84, 85].
In conclusion, the laparoscopic approach should be
the first choice for cholecystectomy in child A and B pa-
tients. The approach to patients with child C or uncom-
pensated cirrhosis remains a matter of debate. As a first
recommendation, cholecystectomy should be avoided in
these patients, unless clearly indicated, such as in ACC
not responding to conservative management [80].
Patients over 80 years old
The true clinical relevance of age is difficult to assess
and the impact of old age on the clinical outcomes in
cases of surgical abdominal pathology is largely
unknown.
In 2017, the WSES and the Italian Society for Geriatric
Surgery developed a CC and a consequent set of guide-
lines on this topic. Only retrospective studies have
focused their interest on elderly patients with ACC. In
general, no RCTs are available, population sizes of the
studies were small and distributed over a long period of
time. It should be noted that the prevalence of elderly
people with ACC could increase in the future, due to the
improvement in life expectancy and the consideration that
the risk of biliary stones increases with age. Some of the
recommendations were derived from evidence describing
the general population, which includes the elderly. The
level of evidence for surgery, timing and risk assessment
ranged from 2 to 3, and the grade of recommendation
ranged from B to C according the 2011 Oxford classifica-
tion “(https://www.cebm.net/wp-content/uploads/2014/06/
CEBM-Levels-of-Evidence-2.1.pdf.)”. With these limita-
tions, the conclusion supported laparoscopic
cholecystectomy for ACC in elderly patients, after consider-
ing the intrinsic surgical risk, life expectancy and the rate of
relapse in cases of conservative management; and frailty
scores, in the absence of a single universally accepted score,
were evaluated as adjunctive tools to better characterize
elderly patients in the clinical situation [9].
More recently, Wiggins et al. have published a retro-
spective study based on an administrative national data-
base of all consecutive patients aged over 80, who were
admitted for ACC in England between 1997 and 2012. It
included a very large number of patients (47,500). On
index admission, non-operative treatment was carried
out for 89.7% of the patients. Then, 7.5% had a chole-
cystectomy, and the remaining 2.8% had a cholecystost-
omy. The three groups were slightly different in mean
age (83, 85 and 85 years, respectively) and the Charlson
Comorbidity Index was below 2 in 87.5%, 83.1% and
83.2%, respectively. When surgery was compared to
non-operative management (NOM) and to cholecystec-
tomy, the mortality rate showed a trend favouring surgi-
cal management. The 30-day mortality rates were 11.6%
for surgery, 9.9% for NOM (p < 0.001) and 13.4% for
cholecystectomy (p < 0.001); the 90-day mortality rates
were 15.6% for surgery, 16.1% for NOM (p > 0.05) and
22.5% for cholecystectomy (p < 0.001); the 1-year mor-
tality rates were 20.8% for surgery, 27.1% for NOM and
37% for cholecystostomy (p < 0.001). It should be noted
that this study showed a readmission rate of more than
50% after conservative management, which probably
contributed to the increased mortality rate at 90 days
and 1 year in this group. Interestingly, the proportion of
cholecystectomies performed laparoscopically increased
from 27 to 59% between 2006 and 2012. Moreover,
multivariate analysis showed that, among the surgical
group at the index admission, laparoscopy played an in-
dependent protective role, with an 84% relative risk re-
duction in 30-day mortality (OR 0.16, 95% CI 0.10–0.25)
when compared to open cholecystectomy. In the discus-
sion, the authors pointed out that the results could have
some relationship with the fact that they came from a
nation in which early cholecystectomy in ACC patients,
regardless of age, is applied only in 15.7% of cases, as
compared to 52.7% in the USA [86].
With a decreased cut-off at 70 years old for the defin-
ition of elderly patients, the safety of ELC in ACC has
also been supported by Loozen et al. in a systematic re-
view and meta-analysis published in 2017. The cumula-
tive morbidity and mortality were 24% and 3%,
respectively, and there was a higher rate of complica-
tions for non-elderly patients. The protective role of
laparoscopy is therefore confirmed; however, the authors
highlight that there are limitations to their findings, in
that there was an absence of prospective studies in-
cluded in the review [11].
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In conclusion, despite the low quality of evidence, the
studies detailed here universally favour ELC for elderly
patients, even for patients older than 80 years of age.
Due to the generally small functional reserve in the eld-
erly, care should be taken to ensure that a prompt thera-
peutic decision is taken and that a high level of expertise
is provided, both intraoperatively and during the postop-
erative management.
Patients who are pregnant
The literature evidence for pregnant patients is limited.
The incidence of ACC during pregnancy varies among
reports, ranging from one case per 1600 pregnancies to
one case per 10,000 pregnancies. However, ACC during
pregnancy is the second reason for non-obstetrical ab-
dominal emergency surgery after appendicitis [87, 88].
The diagnostic criteria and tools are the same used for
the general population [89], but it is of note that leuco-
cytosis during pregnancy could be misleading, and that
the Murphy sign could be difficult to evaluate in the late
part of the third trimester.
The best option for the management of ACC should
be chosen considering a balance among the following
factors: the risk of complications from ACC, limitations
on medication availability depending on the trimester,
the risk of relapse, the risk of other specific conditions
which may occur during pregnancy and the time until
delivery or maturation of the foetus.
In general, in the absence of contraindications, surgery
is suggested as first-line therapy in order to avoid com-
plications and potential drug toxicity for the foetus.
Retrospective studies stated that recurrent ACC or pan-
creatitis can occur in 10% of patients, while miscarriage
can occur in 10–20% of patients [90]. NOM is an alter-
native option, but it must be highlighted that there is a
risk of higher incidence of spontaneous abortion, threat-
ened abortion, and premature birth when compared to
patients who underwent cholecystectomy [91].
One systematic review and meta-analysis focused on
the comparison of open cholecystectomy with laparo-
scopic cholecystectomy during pregnancy [92]. The au-
thors selected 11 studies, all of which were retrospective:
two from national databases, one from a state database
and the others were retrospective from single- or mul-
tiple- institutions. The analysis included 10,632 patients
(1219 open; 9413 laparoscopic). The outcomes were as
follows:
– Outcomes for the mother: death occurred in 1 open
versus 0 laparoscopic cases; complications (including
caesarean section, dilatation and curettage,
hysterectomy, maternal dehydration and pre-
eclampsia) were 3.5% in laparoscopic cases vs. 8.2%
in open cases, with an odds ratio (OR) of 0.42 (95%
CI 0.33–0.53, p < 0.001).
– Outcomes for the foetus: 1 death out of 161 patients
(0.6%) in laparoscopic cases versus 4 deaths from 93
patients (4.3%) in open cases, with an OR of 0.39
(95% CI 0.07–2.19, p = 0.29); the complications
(including foetal loss, foetal distress, threatened
preterm delivery and preterm birth) were 346 out of
8807 laparoscopic cases (3.9%) vs. 139 out of 1161
open cases (12.0%), with an OR of 0.42 (95%; 0.28–
0.63, p < 0.001).
– Surgical complications (including bile duct injury,
bile duct leaking, solid organ or hollow viscus injury,
pulmonary and wound infections, and hernias): 901
out of 9413 laparoscopic cases (9.6%) versus 211 out
of 1219 open cases (17.3%), with an OR of 0.45 (95%
CI 0.25–0.82, p = 0.01).
– Preterm delivery (< 37-week gestation): 11 out of
127 laparoscopic cases (8.7%) versus 5 out of 78
open cases (6.4%), with an OR of 1.35 (95% CI 0.41–
5.14; p = 0.59).
– The Apgar score at 5 minutes was the same.
In 2018, another Japanese nationwide retrospective co-
hort study reported similar results [93].
With the limitations of the quality of the studies,
laparoscopy should be suggested for the treatment of
symptomatic gallstones including ACC. The vast major-
ity of studies suggests the second trimester until the ini-
tial part of the third trimester as the best time to
perform laparoscopic cholecystectomy, as there is a
higher risk of miscarriage and toxic effect of anaesthesia
in the first trimester, while concerns are related to the
size of the uterus in the third trimester [92–94].
A systematic review and set of guidelines from the
British Society for Gynaecological Endoscopy, en-
dorsed by the Royal College of Obstetricians and
Gynaecologists, have been published in 2019 and they
summarize the discussion, confirming the benefits of
ELC over non-operative treatment, especially in the
second trimester [95].
Which surgical strategies should be adopted in case
of difficult anatomic identification of structures dur-
ing cholecystectomy for ACC?
3.4 We recommend laparoscopic or open subtotal
cholecystectomy in situations in which anatomic
identification is difficult and in which the risk of iat-
rogenic injuries is high. #QoE: moderate; SoR:
strong#
Reasons for a ‘difficult gallbladder’ vary, and can be re-
lated to obesity, adhesions, acute or chronic inflamma-
tion, distended gallbladder and liver cirrhosis. Due to
the diversity of reasons and the variability of approaches
among surgeons, a review conducted in 2011 showed no
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consensus on the ideal way to deal with a difficult
gallbladder. The options include subtotal cholecystec-
tomy, fundus first cholecystectomy, perioperative
cholangiogram, open conversion or a combination of
these options [96].
In this section, we focus on subtotal cholecystectomy,
which is an option when the critical view of safety [97]
cannot be obtained. In 2015, a systematic review and
meta-analysis by Elshaer et al. reported that subtotal
cholecystectomy was performed using laparoscopic
(72.9%) open (19.0%) and laparoscopic converted to
open (8.0%) techniques. In this study including over
1200 patients, the most common indications were severe
cholecystitis (72.1%), followed by gallstones in liver cir-
rhosis and portal hypertension (18.2%) and empyema or
a perforated gallbladder (6.1%). They concluded that
subtotal cholecystectomy might be helpful during the
surgical management of difficult cholecystectomy; also
considering that it achieves morbidity rates compar-
able to those reported for total cholecystectomy in
straightforward cases. The quality of evidence is lim-
ited, due to the absence of prospective randomized
studies, which are not expected to be easily per-
formed in the future [85].
Support for subtotal cholecystectomy has also been re-
ported from other studies. In a retrospective study on
severely difficult gallbladders [98], 105 patients who
underwent laparoscopic cholecystectomy were matched
with 46 patients who underwent subtotal laparoscopic
cholecystectomy. The authors observed no bile duct
injury in the subtotal cholecystectomy group, but four
instances in the complete cholecystectomy group. Bile
leakage was greater in the subtotal group due to
difficulty in the cicatrisation on the remaining gallblad-
der stump; however, bile leakage was managed easily by
abdominal drainage or in combination with endoscopic
biliary prosthesis placement.
A recent nation-based database study evaluating 290,
855 cases between 2003 and 2014 showed an increased
use of subtotal cholecystectomy from 0.1 to 0.52% for
open subtotal cholecystectomy and from 0.12 to 0.28%
for laparoscopic cholecystectomy. The conversion rate
from laparoscopic to open total cholecystectomy
decreased from 10.5 to 7.6%. Interestingly, the teaching
hospitals significantly increased the rate of subtotal
cholecystectomy [99]. Furthermore, it should be
highlighted that there are different techniques to achieve
subtotal cholecystectomy: this aspect could add some
difficulty in analysing data from different studies [100].
The quality of the available evidence ranges from low
to moderate. However, the concordance of all the evi-
dence, the large application of the technique globally,
with the important clinical impact on patient safety, and
the current absence of opportunities to achieve a better
level of evidence strongly supports the recommendation
for subtotal cholecystectomy in cases of difficult
gallbladder.
When should conversion from laparoscopic to open
cholecystectomy be considered in patients with ACC?
3.5 We recommend conversion from laparoscopic
to open cholecystectomy in case of severe local in-
flammation, adhesions, bleeding from the Calot’s tri-
angle or suspected bile duct injury. #QoE: moderate;
SoR: strong#
This recommendation should be supported by studies
in which the patients with difficult gallbladder have been
randomized to conversion or to different laparoscopic
procedures. However, this type of study is unlikely to be
performed.
The present update of the WSES Guidelines on ACC
clarifies that, in 2016, the reasons for conversion were
used as a proxy in the absence of high-quality studies;
we maintained the same approach for the current ver-
sion of the guidelines [7, 101, 102].
When expertise in difficult instances of laparoscopic
cholecystectomy is ensured, the conversion is not a fail-
ure and it represents a valid option to be considered.
The quality of the evidence is moderate. However, the
absence of opportunities to achieve a higher quality of
evidence, along with the broadly used conversion to
open surgery and the clinical impact on patients’ safety,
suggests a strong recommendation for conversion to
open surgery after laparoscopy has been attempted at
the best institutional level available. Nevertheless, ac-
cording to Gupta et al., surgeons should adopt a philoso-
phy of safe laparoscopic cholecystectomy. Understanding
the mechanisms related to specific complications may
help elaborating strategies to avoid or reduce those com-
plications; in this context, the surgeon should define, in
their own personal armamentarium, the indications for a
bailout techniques among the available options [103,
104].
Section 4. Timing of cholecystectomy in people
with ACC
When is the optimal timing for laparoscopic chole-
cystectomy in patients with ACC?
4.1 In the presence of adequate surgical expertise,
we recommend ELC be performed as soon as pos-
sible, within 7 days from hospital admission and
within 10 days from the onset of symptoms. #QoE:
moderate; SoR: strong#.
Comment: ELC so defined is preferable to intermedi-
ate laparoscopic cholecystectomy (ILC, performed be-
tween 7 days of hospital admission and 6 weeks) and
DLC (performed between 6 weeks and 3 months).
4.2 We suggest DLC to be performed beyond 6
weeks from the first clinical presentation, in case
Pisano et al. World Journal of Emergency Surgery           (2020) 15:61 Page 13 of 26
ELC cannot be performed (within 7 days of hospital
admission and within 10 days of onset of symptoms).
#QoE: very low; SoR: weak#.
Surgery is currently the recommended treatment in
people with acute cholecystitis. Conservative manage-
ment with fluids, analgesia and antibiotics is an option
for people with mildly symptomatic acute cholecystitis
(i.e. people without peritonitis or those who have wors-
ening clinical condition). In a RCT with long-term
follow-up of 14 years, about 30% of patients treated
conservatively developed recurrent gallstone-related
complications and 60% of patients had undergone chole-
cystectomy subsequently [105, 106]. The study included
only 33 patients and had high risk of bias [105, 106].
Therefore, until new high-quality evidence becomes
available, laparoscopic cholecystectomy is considered the
recommended treatment for patients who are fit to
undergo surgery.
In patients with moderate or severely symptomatic
cholecystitis or in those with mildly symptomatic acute
cholecystitis who prefer surgery, laparoscopic cholecyst-
ectomy is preferred over open cholecystectomy [75]. The
timing of laparoscopic cholecystectomy in these patients
is controversial. A Cochrane review published in 2013
concluded that ELC for acute cholecystitis seems safe
and may shorten the total hospital stay [107].
An update of the literature searches was performed for
the purpose of this guideline. Sixteen trials were identi-
fied in the update (including the trials originally included
in the systematic review) [108–123]. The number of
participants with acute cholecystitis was not reported in
one of the trials [121]. In the remaining 15 trials, 1240
participants were included in 14 trials comparing ELC
versus DLC [108–115, 117–120, 122, 123] and 618
participants were included in one trial comparing ELC
versus intermediate laparoscopic cholecystectomy (ILC)
[116]. The country; recruitment period; number of
participants; the duration of symptoms; the timing of
ELC, DLC and ILC; and the surgical experience are
reported in Table 3. Overall, it appears that ELC was
performed within 10 days of onset of symptoms in most
trials.
There were no significant differences in mortality or
conversion to open cholecystectomy between the three
groups. The proportion of patients with serious adverse
events was significantly higher in ILC compared to ELC
in the only trial included in the comparison between
ILC and DLC [116]. The number of serious adverse
events was significantly less with ELC compared to DLC
in the only trial comparing ELC with DLC that reported
this information [111]. The total length of hospital stay
(including all the admissions for treatment) was about 4
days shorter with ELC compared to DLC [109–112, 115,
117–120, 123], and about 5 days shorter with ELC
compared to ILC [116]. The return to work was about 9
days sooner following ELC compared to DLC [109, 120].
Overall, it appears that ELC performed within 7 days
of hospital admission and within 10 days of onset of
symptoms is superior to either ILC performed between
7 days of hospital admission and 6 weeks or DLC per-
formed between 6 weeks and 3 months of the initial hos-
pital admission for acute cholecystitis. Since blinding
cannot be achieved in these comparisons and the out-
comes were subjective, all the trials were deemed to be
at high risk of bias. However, trials with low risk of bias
are difficult to conduct in this comparison. Since the evi-
dence was consistent across trials and outcomes, it ap-
pears highly likely that ELC is superior to either ILC or
DLC. Therefore, despite the moderate quality evidence
(which is mainly because of the lack of blinding in the
trials), the recommendation for ELC is strong. However,
it should be noted that the study authors described that
ELC was more complex; therefore, it should be
attempted only by experienced surgeons. Referral to cen-
tres with high surgical expertise should be considered if
adequate surgical expertise is not available. If ELC can-
not be performed, DLC appears to be better than ILC.
Although, there is no evidence of difference between
DLC and ILC, the ACDC trial comparing ELC versus
ILC showed that a significant proportion of patients
undergoing ILC developed serious adverse events [116].
Therefore, DLC may be preferable when ELC is not pos-
sible, although a proportion of patients with planned
DLC approach may need unplanned earlier surgery (see
Fig. 1) [107]. There are no trials comparing ILC and
DLC and it is unlikely that they will performed, given
the results of the ACDC trial [116]. Therefore, there is
significant uncertainty whether DLC is better than ILC
when ELC is not possible and the recommendation to
perform DLC when ELC is not possible is weak.
Section 5. Risk prediction in ACC
How can the prognosis and surgical risk be assessed
for patients with ACC?
5.1 We cannot suggest the use of any prognostic
model in patients with ACC.
#QoE: very low; SoR: weak#
Comment: There is currently significant uncertainty in
the ability of prognostic factors and risk prediction
models in predicting outcomes in patients with ACC.
Cholecystectomy is currently the recommended treat-
ment for patients with acute cholecystitis. Laparoscopic
cholecystectomy is preferred over open cholecystectomy
in patients with acute cholecystitis, but it is a major sur-
gical procedure. While it is considered relatively safe, it
is associated with a mortality rate between 0.1 and 1%
[124–126], a risk of bile duct injury in approximately
0.2% to 1.5% of cases [125, 127] and a risk of major
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complications (such as myocardial infarction, heart fail-
ure, acute stroke, renal failure, pulmonary embolism,
lung failure or postoperative shock) in between 6 and 9%
of cases [124].
Observation is an alternative option for patients with
mildly symptomatic ACC (i.e. in patients without peri-
tonitis or in those who have worsening symptoms). After
a long-term follow-up of 14 years, about 30% of patients
with mildly symptomatic acute cholecystitis who did not
undergo cholecystectomy developed recurrent gallstone-
related complications, compared with 3% of patients
who underwent cholecystectomy. These differences were
not significant for recurrent disease or overall complica-
tions [128]. However, 60% of patients had undergone
surgery, and the study was small and carried a high risk
of bias; therefore, there is lot of uncertainty as to
whether it is better to perform surgery or observation in
patients with mildly symptomatic acute cholecystitis.
Identification of patients at high risk of complications
and mortality can help in optimising them prior to sur-
gery or in deciding whether referral to high-volume cen-
tres and specialized centres, which may decrease the
complications [129, 130], is appropriate. Informed deci-
sions about whether to opt for surgery or observation
can also be made if information on the risks is available.
We performed a systematic review of studies reporting
on the ability of prognostic factors or risk prediction
models to predict important patient-related outcomes,
Table 3 Timing of cholecystectomy in people with ACC




Timing of surgery in
intermediate or delayed group
Number of participants in





< 4 days after diagnosis 27 2 months after discharge 36 Unclear
Gul 2013 (2) < 72 h after hospital
admission
30 6 to 12 weeks after initial
conservative treatment
30 High
Gutt 2013 (3) < 24 h after hospital
admission





< 7 days of diagnosis 74 6 to 8 weeks after discharge 71 Low
Kolla 2004
(5)
< 24 h after
randomisation
20 6 to 12 weeks after the acute
episode subsides
20 Low
Lai 1998 (6) < 24 h after
randomisation
53 6 to 8 weeks after the acute
episode subsides
51 Low
Lo 1998 (7) < 72 h after admission 45 8 to 12 weeks after discharge 41 High
Macafee
2009 (8)
< 72 h after recruitment Not stated 3 months after discharge Not stated High
Mustafa 2016
(9)
< 48 to 72 h of diagnosis 105 6 to 12 weeks after initial attack 105 High
Ozkardes
2014 (10)





< 72 h after occurrence
of symptoms





During day as soon as
possible
42 6 weeks after initial diagnosis 44 High
Saber 2014
(13)
< 72 h of duration of
symptoms










As soon as possible 25 6 to 8 weeks after discharge 25 High
Zahur 2014
(16)
< 24 to 48 h after
hospital admission
47 6 to 8 weeks after initial
conservative treatment
41 High
Main reasons for unclear or high risk of bias
High risk of bias: at least one of random sequence generation, allocation concealment, missing outcome bias or selective outcome reporting bias was classified as
high risk of bias
Unclear risk of bias: at least one of random sequence generation, allocation concealment, missing outcome bias or selective outcome reporting bias was classified
as unclear risk of bias without any of the domains being classified as high risk of bias
aAll studies were at high risk of bias due to lack of blinding. The risk of bias classification stated here is for the remaining domains
bThis was the only study in which intermediate laparoscopic cholecystectomy was performed; delayed laparoscopic cholecystectomy was performed in the
remaining studies
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such as mortality, complications and conversion to open
surgery in patients with ACC [131]. In this systematic
review and meta-analysis, we included 12 studies and
6827 patients in one or more analysis. Only a few factors
(TG13, age, male gender, previous abdominal surgery,
diabetes, hypertension and C-reactive protein) were re-
ported in a format similar enough to allow comparisons
between studies. The remaining factors were studied in
single studies or using different thresholds. Therefore,
there is no information on their reproducibility, and the
results may be unreliable.
Among the prognostic factors reported in at least two
studies, TG13 grade 3 had an increased risk of all-cause
mortality compared to grade 1. The risk increased from
a median risk of 1.3% to 6.5% (95% CI 3.7–11.2). How-
ever, most studies included only people who underwent
surgery, not all of whom were patients with ACC. There
have been no RCTs of surgery versus observation in
people with severe ACC. Laparoscopic cholecystectomy
performed by experienced surgeons had lower major
complication rates than percutaneous cholecystostomy
with no planned cholecystectomy [11]. Therefore, it ap-
pears that, despite the increased risk of mortality in
TG13 grade 3 compared to TG13 grade 1, surgery seems
to be the preferred option when possible. However, re-
ferral to high volume centres and specialized centres
may decrease the complications [129, 130] and resulting
mortality, and should be considered in people with
TG13 grade 3 acute cholecystitis.
Being male was associated with an increased risk of
complications (from 10 to 15%; 95% CI 10.5–20.9) and an
increased risk of conversion to open cholecystectomy
(from 16 to 48.5%; 95% CI 27.5–70.0). The reasons for the
difference in the complications and conversion between
males and females are not clear, but may be due to a com-
bination of increased skeletal muscle mass [132] (particu-
larly in the trunk [133]) and increased visceral abdominal
fat in males [132, 134, 135], which could make laparo-
scopic surgery more difficult, and a common delay in
males seeking medical help due to a misguided perception
of masculinity [136, 137], which could mean that the
males had more severe disease than females at the time of
presentation to the hospital. Previous upper abdominal
surgery is a risk factor for conversion to open cholecystec-
tomy. This is to be expected because of the intra-
abdominal adhesions related to previous abdominal sur-
gery [138]. An increased age had a minor increase in the
conversion to open cholecystectomy, but the increase is
cumulative, as elderly patients may have a clinically signifi-
cant increase in conversion to open cholecystectomy com-
pared with young people. Various confounding factors
such as comorbidities and increased cumulative risk of
upper abdominal surgery may contribute to the increased
risk of conversion to open cholecystectomy.
However, it should be noted that the systematic review
included only preoperative factors, and most of the stud-
ies included only patients undergoing cholecystectomy
for ACC. Therefore, the findings of the review are ap-
plicable only for preoperative risk prediction in patients
undergoing cholecystectomy for ACC.
It should also be noted that most of the studies were
retrospective, in which blinding of predictor or outcome
measurement were not reported, and most of the studies
were small.
Overall, there is significant uncertainty in the ability of
prognostic factors and risk prediction models in predict-
ing outcomes in patients with ACC. TG13 grade 3 may
be associated with greater mortality than grade 1 severity
of acute cholecystitis. Despite the increased risk of
mortality in TG13 grade 3 compared to TG13 grade 1,
surgery seems to be the preferred option when possible.
The TG18 adopted the TG13 severity grading criteria in
predicting outcomes in patients with ACC [14].
High-quality studies are necessary to provide better in-
formation on the prognostic factors of patients with
acute cholecystitis and to improve shared decision
making.
Section 6. Alternative treatment for patients with
ACC who are not suitable for surgery: observation
and techniques for gallbladder drainage
When should Non-Operative Management be consid-
ered for patients with ACC?
6.1 We suggest considering NOM, i.e. best medical
therapy with antibiotics and observation, for patients
refusing surgery or those who are not suitable for
surgery. #QoE: low; SoR: weak#
6.2 We suggest considering alternative treatment
options for patients who fail NOM and who still
refuse surgery or patients who are not suitable for
surgery. #QoE: low; SoR: weak#
Schimdt et al. [105] published an RCT comparing ob-
servation and surgery in cases of ACC, with a long me-
dian follow-up time of 14 years. In their analysis, about
30% of patients with mildly symptomatic acute chole-
cystitis who did not undergo cholecystectomy developed
recurrent gallstone-related complications, as compared
with 3% of patients who underwent cholecystectomy,
but these differences were not significant for recurrent
disease or complications. Overall, 60% of patients had
undergone surgery, while 40% avoided surgery. There
are significant limitations in the study, as recognized by
the authors: firstly, a relevant percentage of eligible pa-
tients (41%) were excluded from randomization; sec-
ondly, the reasons for the exclusion were not stated in
the paper; thirdly, the definitions of dropout and failure
within the observation group were not clear. Brazzelli
et al. [139] published a systematic review of two RCTs
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comparing observation with surgery in patients with
symptomatic gallstone disease (in the first study) and pa-
tients with ACC (in the second study). From a total of
201 patients, the results confirmed the high rate of
gallstone-related complications within the observation
group (RR 6.63, 95% CI 1.57–28.51, p = 0.01).The au-
thors, although noting the substantial lack of good qual-
ity evidence, reported that a policy of surgery for all
patients with ACC, when compared to a policy of obser-
vation followed by surgery for symptomatic patients,
represents a costly but more effective choice. In conclu-
sion, relevant uncertainty exists regarding the best man-
agement between surgery or observation in cases of
ACC, especially in uncomplicated disease; observation
and best medical therapy are likely to be safe, but this
latter approach is characterised by a high incidence of
recurrent disease.
Alternative treatment options may be considered for
patients who fail NOM for ACC, also considering the in-
dividual patient’s characteristics and the clinical
situation.
Which is the first-choice treatment for ACC in high
risk patients?
6.3 Immediate laparoscopic cholecystectomy is su-
perior to percutaneous transhepatic gallbladder
drainage (PTGBD) in high risk patients with ACC.
We recommend laparoscopic cholecystectomy as the
first-choice treatment in this group of patients.
#QoE: high; SoR: strong#
TG13 on ACC [140] considered gallbladder drain-
age as mandatory for patients with severe grade ACC
(according to the Tokyo classification [10] of acute
cholecystitis) and also suggested its use in the moder-
ate grade if conservative treatment fail. The revised
TG18, based on recent studies, proposed that severe-
grade cholecystitis, under certain strict criteria, may
be treated with laparoscopic cholecystectomy [10,
140]. A systematic review published in 2016 compar-
ing percutaneous transhepatic gallbladder drainage
(PTGBD) and cholecystectomy in critically ill patients
reported no benefit for the use of PTGBD over chole-
cystectomy [141]. Six studies were analysed with a
total of 337,500 patients. Mortality rate, length of
hospital stay and number of readmissions for
gallstone-related diseases were all significantly higher
in the PTGBD group than in the cholecystectomy
group. It should be noted that all included studies
had a retrospective design, which makes the results
prone to bias. Recently, the first randomized trial on
this subject was published (the CHOCOLATE trial).
The results showed that laparoscopic cholecystectomy
is superior to PTGBD [11] also in high-risk patients
with ACC. PTGBD was compared with ELC in critic-
ally ill patients (APACHE score 7–14) with ACC, in
terms of efficacy and safety. Patients who underwent
ELC had significantly fewer major complications,
which were mainly recurrent biliary events. Five per-
cent of patients who underwent ELC had complica-
tions, compared with 53% of patients who underwent
PTGBD. Mortality was low and remained the same in
both groups.
Early laparoscopic cholecystectomy also led to signifi-
cantly less utilisation of health care resources. The trial
concluded that immediate cholecystectomy in high-risk
patients is safe and should be the standard of care.
What is the role of gallbladder drainage in patients
with ACC who are not suitable for surgery?
6.4 We recommend performing gallbladder drain-
age in patients with ACC who are not suitable for
surgery, as it converts a septic patient with ACC into
a non-septic patient. #QoE: moderate; SoR: strong#
Patients who are not suitable for surgery, but who are
septic due to gallbladder empyema, are effectively
treated by PTGBD, as shown in the CHOCOLATE trial
[11]. Gallbladder drainage decompresses the infected bile
or pus in the gallbladder, removing the infected collec-
tion without removing the gallbladder. The removal of
the infected material can result in reduced inflammation
and in improvement of the clinical conditions. Several
case series, both retrospective and observational, exist
on cholecystostomy. A systematic review of the literature
included 53 studies with 1918 patients outlining a high
success rate of the procedure (85.6%) with a low
procedure-related mortality rate (0.36%); however, the
30-day mortality rate was high at 15.4% [142]. A major
limitation of the study was the inclusion of patients with
both acute acalculous cholecystitis and ACC. A review
of additional 27observational studies on cholecystostomy
[143] showed significant heterogeneity in terms of inclu-
sion criteria, results and conclusions reached by different
authors. Considering these limitations, the reported in-
hospital mortality and morbidity rates for cholecystost-
omy range from 4 to 50 % and from 8.2 to 62%,
respectively.
Gallbladder drainage may be an option in patients
who failed conservative management after a variable
time of 24 to 48 h and who present with strict contrain-
dications for surgery. A prospective study by Barak et al.
[144] reported that age over 70 years, diabetes, tachycar-
dia and a distended gallbladder at admission are
predictors for failure of NOM at 24-h follow-up, while a
WBC of more than 15,000 cell/mm3, fever and age
above 70 years were predictors for failure of NOM at
48-h follow-up.
No specific antibiotic regimen is to be prescribed
alongside PTGBD and no evidence exists supporting the
need for a specific antibiotic regimen. For the antimicro-
bial therapy, please refer to the dedicated section.
Pisano et al. World Journal of Emergency Surgery           (2020) 15:61 Page 17 of 26
Should delayed cholecystectomy be offered to pa-
tients with ACC after the reduction of perioperative
risk?
6.5 Delayed laparoscopic cholecystectomy is sug-
gested after reduction of perioperative risks to de-
crease readmission for ACC relapse or gallstone-
related disease. #QoE: very low; SoR: weak#
De Mestral et al. published a large retrospective epide-
miologic analysis in 2013, showing that 40% of patients
underwent a DLC after PTGD; the 1-year readmission
rate for patients who did not undergo DLC after PTGD
was 49% with an in-hospital mortality rate of 1% [145].
No randomized trial currently exists comparing DLC to
observation alone.
Can endoscopic gallbladder drainage be considered
an alternative to PTGBD in patients with ACC who
are not suitable for surgery?
6.6 In patients with ACC who are not suitable for
surgery, endoscopic transpapillary gallbladder drain-
age (ETGBD) or ultrasound-guided transmural gall-
bladder drainage (EUS-GBD) should be considered
safe and effective alternatives to PTGBD, if per-
formed in high-volume centers by skilled endosco-
pists. #QoE: high; SoR: strong#
ACC is a frequent event in urgent surgical settings,
and the gold standard for its treatment is laparoscopic
cholecystectomy [140, 146, 147]. However, some patients
are unfit for surgery, and for them non-surgical drainage
represents a suitable option, either as a bridge to subse-
quent surgery, once their clinical conditions improve, or
as a definitive treatment for those who remain poor can-
didates for surgery. Non-surgical approaches include
PTGBD and endoscopic procedures. Among these, alter-
natives are endoscopic transpapillary gallbladder drain-
age (ETGBD), with placement of a transpapillary naso-
gallbladder drainage tube (ENGBD) or double-pigtails
tent (EGBS), or transmural ultrasonography-guided gall-
bladder drainage (EUS-GBD) [148].
In a systematic review about options for endoscopic
gallbladder drainage, Itoi et al. [149] reported a pooled
technical success rate of ENGBD of 80.9% (95% CI
74.7–86.2) and a pooled clinical response rate of 75.3%
(95% CI 68.6–81.2%). For EGBS, the results were 96%
(95% CI 91.1–98.7) and 88% (95% CI 81.2–93.2), re-
spectively. At that time, only small case-series were
available for EUS-GBD, with reported technical and clin-
ical success rates of 100% (95% CI 75.3–100).
Five years later, Itoi et al. [150], in a RCT of 73 con-
secutive patients with ACC, obtained overall technical
success rates with ENGBD and EGBS of 91.9% and
86.1%, respectively, whereas the clinical success rates by
intention-to-treat analysis were 86.5% and 77.8%, re-
spectively. The authors argued that the lower clinical
success rate may be ascribed to inadequate gallbladder
drainage when large stones or pus were present, and to
the use of small-diameter catheters or stents.
EUS-GBD has been compared, in terms of technical
feasibility and efficacy, to PTGBD [151] inpatients with
acute, high-risk or advanced stage cholecystitis who did
not respond to initial medical treatment and could not
undergo ELC. EUS-GBD and PTGBD showed similar
technical (97% vs. 97%, p = 0.001) and clinical (100% vs.
96%, p = 0.0001) success rates, and similar rates of com-
plications (7% vs. 1%, p = 0.492), indicating that EUS-
GBD is a safe alternative to PTGBD in patients who are
unsuitable for surgery.
Irani and co-workers [152] reached similar conclusions
after a retrospective multicenter study, in which the
technical success rates of EUS-GBD and PTGBD were
98% and 100% (p = 0.88), respectively. Moreover, the
EUS-GBD group had a shorter in-hospital length of stay
and fewer repeat interventions (p < 0.05).
Khan et al. [153], in a meta-analysis, evaluated the
technical success rates and post-procedure adverse
events of ETGBD compared with PTGBD. They found
that the pooled OR for technical success of ETGBD ver-
sus PTGBD was 0.51 (95% CI 0.09–2.88; I2 = 23%) and
for post-procedures adverse events was 0.33 (95% CI
0.14–0.80; I2 = 16%) in favour of ETGBD. The weighted
pooled rates (WPRs) for EUS-GBD were as follows:
technical success 93% (95% CI 87–96; I2 = 0%), clinical
success 97% (95% CI 93–99; I2 = 0%), post-procedure
adverse events 13% (95% CI 8–19; I2 = 0%) and recur-
rent cholecystitis 4% (95% CI 2–9; I2 = 0%).
In a prospective study on long term-follow up after
EUS-GBD [154], the recurrence of cholecystitis was ob-
served in 7.7% of cases, suggesting that this endoscopic
procedure is a safe alternative in the treatment of acute
cholecystitis in high-risk patients.
EUS-GBD has also been proven to be a feasible tech-
nique for the conversion of percutaneous cholecystost-
omy [155]. The advantages of EUS-GBD over PTGBD
include an internalization of bile, obviating the risk of
recurrent cholecystitis following percutaneous catheter
removal and the risk of bleeding, and being associated
with less post-procedural pain [155, 156].
A recent RCT by Teoh et al. [157] identified patients
with ACC at very high risk for surgery as patients older
than 80 years, with an ASA grade ≥ 3 or an age-adjusted
Charlson Comorbidity score > 5 and/or a Karnofsky
score < 50. The authors randomized them to receive ei-
ther EUS-GBD with LAMS or PTGBD within 4 to 6 h
from diagnosis. Although 30-day mortality was equiva-
lent between the two study groups, the results were in
favour of EUS-GBD, which was associated with less ad-
verse events at 30-day (12.8% vs. 47.5%, p = 0.001) and
at 1-year follow-up (25.6% vs. 77.5%, p < 0.001), with a
reduced number of re-interventions at 30 days (2.6% vs.
Pisano et al. World Journal of Emergency Surgery           (2020) 15:61 Page 18 of 26
30%, p = 0.001) and with a reduced number of episodes
of recurrent cholecystitis (2.6% vs. 20%, p = 0.029).
6.7 If endoscopic transpapillary gallbladder drain-
age is performed, both endoscopic nasogatric endo-
scopic gallbladder drainage (ENGBD) and endoscopic
gallbladder stenting (EGBS) should be considered
suitable options, based on patient characteristics and
on the endoscopist’s decision. #QoE: high; SoR:
strong#
Although ENGBD has certain advantages for patients
in whom stent insertion is impossible or when there is
stent dysfunction, it has two major drawbacks: the po-
tential for inadvertent catheter dislodgement or patient
removal, and discomfort. On the other hand, an indwell-
ing stent may be suitable when there is a concern in pa-
tients with altered mental status or dementia [6]. A
meta-analysis conducted in TG18 [140] found no statis-
tically significant difference in technical success (OR
1.18; 95% CI 0.36–3.89), clinical success (OR 1.82; 95%
CI 0.40–8.26), or adverse events rate (OR 1.49; CI 95%
0.29–3.81). Consequently, the advantages and disadvan-
tages of each drainage method are considered approxi-
mately equal.
What is the role of endoscopic transmural
ultrasound-guided gallbladder drainage (EUS-GBD)
in patients with ACC who are not suitable for
surgery?
6.8 EUS-GBD with lumen-apposing self-expandable
metal stents (LAMSs) should be preferred to ETGBD,
if performed by skilled endoscopists. #QoE: moder-
ate; SoR: strong#
In a recent meta-analysis, Khan et al. [153] found that
the proportional difference of WPRs for technical success
and clinical success between EUS-GBD versus ETGBD
were 10% and 4%, respectively. This difference is ex-
plained by the fact that the transpapillary procedures may
be technically challenging, due to the anatomy of the cys-
tic duct or stone impaction. On the other hand, if the dis-
tance between the gallbladder and the enteric lumen is
less than 1 cm, EUS-GBD appears to be safe and feasible
[154–156]. This technique results in a permanent fistula
formation between the gallbladder and the hollow viscus,
facilitating anatomic bile drainage [158].
A variety of plastic stents (straight, single, double-
pigtail) and self-expandable metal stents (SEMSs) have
been used during EUS-GBD with similar treatment out-
comes. However, plastic and SEMSs are tubular stents
not specifically designed for EUS-GBD procedures;
therefore, bile leakage, stent occlusion and migration are
potential adverse events [148, 159]. In order to overcome
these limitations, modified stents with flared ends and
LAMSs have been introduced [159, 160].
LAMSs are fully covered self-expandable metal stents
with bilateral flanges specifically designed for EUS-
guided, trans-enteric drainage of a pseudocyst or non-
adherent fluid collections [148]. The theoretical
advantage of LAMSs over other stents is the ability to
approximate the gallbladder wall to the enteric lumen,
‘sealing off’ any potential bile leaks and preventing mi-
gration, thus providing a robust lumen anchorage [160].
Furthermore, the large diameter of LAMSs (10 mm and
15 mm) may allow access to the gallbladder with a slim
endoscope with the purpose of removing stones, or tak-
ing biopsies [148].
In a retrospective review of multi-center prospectively
collected data, Irani et al. [160] achieved a technical suc-
cess rate of 93% and a clinical success rate of 100% using
LAMSs to decompress the gallbladder in patients who
had ACC and who were poor surgical candidates. Doll-
hopf et al. [161], with a new LAMSs device, obtained
technical and clinical success rates of 98.7% and 95.9%,
respectively, with 10.7% of cases having adverse events.
6.9 If a EUG-GBD is performed using metal stents,
we recommend their removal within 4 weeks, in
order to avoid food impaction with subsequent high
risk of recurrence of ACC. #QoE: low; SoR: weak#
The long-term deployment of metal stents in EUS-
GBD could cause adverse events, including food
impaction, which, by impairing bile flow, may induce
recurrence of cholecystitis. There are several evidences
[159, 162] that a well formed fistula might develop
between the gallbladder and the gastrointestinal tract
within four weeks using a conventional biliary SEMS as
well as a LAMS.
Some authors [162] have argued that, in order to min-
imise the risk of recurrent cholecystitis or biliary leakage,
LAMSs could be left in place for a longer period, with-
out stent-related complications [13]. Although a more
significant tissue reaction can be expected after a long
stented well-time, it seems probable that stent location,
whether gastric or duodenal, might also influence the
degree of tissue overgrowth. The retroperitoneal location
of the duodenum results in a more stable tract to the
gallbladder than the stomach, in which peristaltic move-
ments might result in a more pronounced tissue reac-
tion, impairing the removal of the stent once the
inflammatory process has subsided.
Section 7. Antibiotic treatment of ACC
Which is the optimal antibiotic treatment for patients
with uncomplicated ACC?
7.1 In uncomplicated ACC, we recommend against
the routine use of postoperative antibiotics when the
focus of infection is controlled by cholecystectomy.
#QoE: high; SoR: strong#
An open-label non-inferiority prospective controlled
trial by Regimbau et al. [163] randomized 414 patients
who underwent cholecystectomy for uncomplicated
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ACC to either no antibiotics after surgery or continu-
ation of the preoperative antibiotic regimen for 5 days.
An imputed intention-to-treat analysis showed no differ-
ence in the incidence of postoperative infection rates:
17% (35 out of 207) in the no-treatment group com-
pared with 15% (31 out of 207) in the antibiotic group
(absolute difference 1.93%; 95% CI − 8.98–5.12).
No studies were found on this topic since the publica-
tion of the 2016 WSES Guidelines on ACC.
Which is the optimal antibiotic treatment for
patients with complicated ACC?
7.2 In complicated ACC, we recommend prescrib-
ing the antimicrobial regimen based on the presumed
pathogens involved and the risk factors for major
resistance patterns. #QoE: high; SoR: strong#
Empiric antibiotic treatment should be commenced
according to the most frequently isolated microorgan-
isms, taking into consideration the local trends of anti-
biotic resistance and the availability of drugs. In biliary
infections, Gram-negative aerobes, such as Escherichia
coli and Klebsiella pneumonia, and anaerobes, especially
Bacteroides fragilis are the most commonly isolated bac-
teria [74, 164]. The potential pathogenicity of Entero-
cocci in biliary sepsis remains unclear and specific
coverage against these microorganisms is not routinely
suggested for community-acquired biliary infections
[165]. In case of immunosuppression, i.e. transplant pa-
tients, infection lead by Enterococcus spp. should be pre-
sumed and pre-emptively treated [166]. The main issue
related to antibiotic resistance in biliary tract infections
remains the production of extended spectrum beta-
lactamase by Enterobacteriaceae; this is frequently found
in community acquired infections in patients with previ-
ous exposure to antibiotics [74, 164].
Healthcare-related infections are commonly caused by
resistant bacterial strains, requiring complex antibiotic
regimens; the use of adequate broad-spectrum empiric
therapy appears to be a crucial factor to reduce postop-
erative complications and deaths, especially in critically
ill patients [166]. The efficacy of antibiotics in the treat-
ment of biliary infections may be associated with their
biliary concentration, although few clinical or experi-
mental data exists supporting the use of antibiotics with
biliary penetration for these patients. Nevertheless, in
patients with obstructed bile duct, the biliary penetration
of antibiotics may be poor and the actual bile concentra-
tions are reached only in a small percentage of patients
[167]. Biliary penetration of different antibiotics (indi-
cated as the ratio of bile-to-serum concentrations) are
listed in Table 4 [168].
In the management of critically ill patients with ACC,
the choice of the antimicrobial regimen may be challen-
ging. In patients with sepsis of abdominal origin, the
early administration of a correct empirical antimicrobial
therapy has a significant impact on outcome [169]. Richè
et al. prospectively studied a cohort of 180 consecutive
patients with secondary generalized peritonitis and
found that there was a significantly higher mortality rate
in patients with septic shock than in those without septic
shock (35% and 8%, respectively, OR 4.11; 95% CI 1.78–
9.48, p = 0.0003) [170]. Furthermore, in patients with
septic shock, the biliary origin of peritonitis was a risk
factor for mortality at multivariate analysis (OR 3.5; 95%
CI 1.09–11.70, p = 0.03). International guidelines for the
management of severe sepsis and septic shock (the
Surviving Sepsis Campaign) [171] recommend the ad-
ministration of broad-spectrum intravenous antibiotics
with good penetration into the presumed site of infec-
tion within the first hour. A recent CC (Sepsis-3) [172]
proposed a new evidence-based definition of sepsis and
septic shock, underscoring the importance of recogniz-
ing the septic focus and the infecting organism. In cases
of biliary sepsis, drug pharmacokinetics may be signifi-
cantly altered in patients with organ dysfunction and
septic shock; therefore, the selection of antibiotics
should be reassessed daily and be based on both the
pathophysiological status of the patient and the pharma-
cokinetic properties of the specific drug [173]. No
significant additional evidence was found since the pub-
lication of the 2016 WSES Guidelines on ACC (see
Table 4 for recommended antibiotic regimens).
What is the role of microbiological cultures and
sensitivities in patients with ACC?
7.3 In patients with complicated ACC and patients
at high risk for antimicrobial resistance, we recom-
mend adapting the targeted antibiotic regimen to the
results of microbiological analysis, ensuring adequate
antimicrobial coverage. #QoE: moderate; SoR: weak#
Identifying the causative organism(s) is an essential
step in the management of ACC, especially in patients at
high risk for antimicrobial resistance, such as immuno-
compromised patients and those with healthcare-
associated infections. The rate of positive bile culture
(from either gallbladder culture or bile samples from the
common bile duct) ranges from 29 to 54% in cases of
ACC [174–179].
No additional studies have been found on this topic
since the publication of the 2016 WSES Guidelines on
ACC.
Conclusions, knowledge gaps and research
recommendations
The WSES 2020 on ACC, based on the updated
evidence, reinforces the pivotal role of ELC in the man-
agement of ACC, even in high-risk patients. The new
developed algorithm, in our opinion, emphasizes the
importance of two categories of patients: the high-risk
patients and those who are not suitable for surgery.
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The CHOCOLATE Study [11] defined high-risk
patients as those with an APACHE score 7–14; this
high-quality study improved our understanding of the
management of this complex cohort of patients. Its re-
sults are in favour of surgery, when compared with bil-
iary drainage in high-risk patients with ACC. However,
there is not a single and universally accepted definition
of this high-risk patients group; therefore, accepting the
suggestion coming from Loozen et al., it appears reason-
able to recommend the development of local clinical
pathways after deciding which of the available scores fits
local needs and expertise.
In addition to the defined high-risk patients, the WSES
proposes the category of patients who are not suitable
for surgery. We suggest to include in this group all pa-
tients with ACC who are not fit for surgery, according
to the specific surgeon’s judgement, and patients who
are not amenable for surgical treatment, due to the pres-
ence of clinical conditions which are not classifiable with
clinical or physiologic scores (Appendix 2). For this co-
hort of patients, surgery may be unsafe or impossible
and gallbladder drainage may be the best suitable option
in case of uncontrolled sepsis and/or failure of NOM.
Moreover, areas for important future research were
identified. These include (1) high-quality studies on prog-
nostic factors of ACC patients so as to improve shared de-
cision making, (2) defining the best management option
when ELC is not possible due to lack of surgical expertise
or due to the duration of symptoms. This should include
focus groups involving patients and clinicians, and using
observational studies, and (3) defining the best option in
the management of difficult operative scenarios. This
needs a common language among researchers in order to
obtain higher quality studies (in terms of classification of
difficulties: e.g. adhesions with hollow viscus, difficulties in
grasping the gallbladder, difficulties in view of safety, gan-
grene of the cystic duct, etc.).
Finally, the WSES strongly advocates the adoption of a
policy for safe laparoscopic cholecystectomy and encour-
ages the development of local pathways, based on the
available evidence.
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